OR WAIT 15 SECS
Concerto HealthAI’s real-world data and artificial intelligence capabilities are expected to accelerate outcomes studies and patient insights for Pfizer’s investigational therapies and commercialized therapeutics.
On April 9, 2019, Concerto HealthAI, a company that specializes in oncology-specific real-world data (RWD) and advanced artificial intelligence (AI)-enabled insight solutions for real-world evidence (RWE) generation, announced that it has entered into a collaboration with Pfizer to advance work in precision oncology using Concerto HealthAI’s eurekaHealth platform, AI models and real-world clinical electronic medical record (EMR), and healthcare claims.
The collaboration will conduct novel synthetic control arm and prospective RWD outcomes study designs for both pre- and post-approval therapeutics with the goal of speeding up study completion for Pfizer‘s investigational therapies and commercialized therapeutics used to treat solid tumors and hematologic malignancies. Concerto HealthAI will use data from clinical practices participating in the American Society of Clinical Oncology’s CancerLinQ initiative and others throughout the United States. A joint steering committee will oversee the collaboration. The first outcomes research and publications are expected in early 2020.
This recent partnership builds on work in study designs based on RWD that CancerLinQ, Concerto HealthAI, and others have conducted in collaboration with FDA, which was announced in August 2018. Concerto HealthAI also announced a multi-year strategic agreement with Bristol-Myers Squibb in March 2019 that will cover a range of cancers, integrate multiple data sources, and apply AI and machine learning to accelerate clinical trials, enable robust protocol design, and generate insights for precision oncology treatment and improved patient outcomes.
Source: Concerto HealthAI